Indian J Pharm Close
 

Figure 1: Second line EFS comparison for patients with event free survival of >6 months versus ≤6 months with first-line therapy

Figure 1: Second line EFS comparison for patients with event free survival of >6 months versus ≤6 months with first-line therapy